Navigation Links
Clinical Trial Results of Pollogen's TriPollar(TM) Radio Frequency Technology published in the Journal of the European Academy of Dermatology and Venereology
Date:6/2/2009

TEL AVIV, Israel, June 2 /PRNewswire/ -- Clinical trial results using the regen(TM) system, the newest aesthetic solution powered by 3rd generation TriPollar RF technology on cellulite treatment and body contouring, have been published in the online Journal of the European Academy of Dermatology and Venereology. The peer reviewed study, conducted by Dr. Manuskiatti et al. at the Mahidol University Hospital, Bangkok entitled "Circumference reduction and cellulite treatment with a TriPollar radiofrequency device: a pilot study" was accept in February 2009, and is available online at http://www3.interscience.wiley.com/journal/122312206/abstract

The study demonstrated long term measurable and durable body circumference and fat thickness reduction using objective measurement system (imaging Ultrasound). The study involved 37 patients treated once a week with the regen system for a total of eight treatments. Results showed that there was significant circumference reduction of 3.5 cm on average at the abdomen with a maximum of 14.4 cm, and 1.71 cm reduction at the thigh with a maximum of 9.1 cm. These results were maintained four weeks following the last treatment. In addition, ultrasound measurements of the distance between the epidermis and the superficial fascia showed an average reduction of 10.5% in the thickness of adipose tissue with a maximum reduction of 39% at the thigh region.

"TriPollar is a truly innovative technology that delivers what patients worldwide have been waiting for- a pain free, safe and effective solution for body contouring. The latest study clearly demonstrated that TriPollar RF technology provides beneficial effects on the reduction of abdomen and thigh circumferences and an overall improvement in the appearance of cellulite." said Dr. Manuskiatti, lead investigator for Pollogen's clinical trial and Associate Professor at the Department of Dermatology at the Siniraj Hospital, Thailand.

Ms. Yfat Scialom, CEO of Pollogen commented: "The study show that the innovative TriPollar RF technology, developed by Pollogen, delivers consistent and effective results without pain and adverse side effects as proven once again by the leading scientists and labs in the world. Our customers worldwide are benefiting from the most advance RF technology bringing safe, effective solution to a new standard. Since the launch of Pollogen's professional anti-aging and body contouring products two years ago, we have successfully captured the attention of physicians and estheticians in over 50 countries world wide, and we look forward to continued success in the future."

About Pollogen:

Pollogen Ltd. develops, manufactures and markets professional medical aesthetic devices, powered by the TriPollar(TM) 3rd generation Radio Frequency (RF) technology. Invented and perfected by Pollogen, proprietary TriPollar(TM) technology powers a full line of clinically-proven, non-invasive and non-surgical treatment platforms for wrinkles, cellulite, circumference reduction and skin tightening. The flagship aesthetic devices, apollo(TM) and regen(TM) offer customers clinically-proven, safe and effective anti-aging beauty treatments that deliver immediate and long-lasting results. To learn more, please visit the Pollogen website at http://www.pollogen.com

    Contact:
    Name: Abigail Marks
    Tel: +972-54-244-5807
    E-mail: abigail_m@pollogen.com



'/>"/>
SOURCE Pollogen Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... -- Boston Scientific Corporation (NYSE: BSX ) ... assets and capabilities of the Neovasc, Inc., (NASDAQ: ... as well as a 15% equity stake in Neovasc, ... Neovasc advanced biological tissue business makes elements used in ... System. * Upon completion of the transaction, the ...
(Date:12/2/2016)... , Dec. 2, 2016 Lianluo ... Smart" or "the Company") which develops, markets and ... in China and international ... Disease Diagnosis and Treatment New Progress Forum, co-hosted ... Guangdong Province , Guangdong Provincial People,s ...
(Date:12/2/2016)... 2016 On Thursday, the NASDAQ Composite ... while the Dow Jones Industrial Average managed to stay in ... markets, which prompted Stock-callers this morning to look at the ... NUVA ), Smith & Nephew PLC (NYSE: ... and Cesca Therapeutics Inc. (NASDAQ: KOOL ). You ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... , ... Sourced from the Isbre Springs beneath the 5,000 year old Hardanger ... of just 6 ppm TDS (Total Dissolved Solids) in addition to its excellent taste ... several ShopRite and FoodTown stores in NJ and received rave comments from consumers. , ...
(Date:12/2/2016)... ... December 02, 2016 , ... Clarify Health ... has raised $6.0 million in an initial round of funding. The round was ... and their caregivers can receive far better care through the application of the ...
(Date:12/2/2016)... ... ... ‘Tis the season for giving! Today, 20 creative teams across the nation ... the Drug Enforcement Administration as part of the National Red Ribbon Week Photo Contest. ... decorated their campuses with this year’s Red Ribbon Week theme: “YOLO. Be Drug Free,” ...
(Date:11/30/2016)... ... November 30, 2016 , ... Standard ... 75, an annual ranking and recognition of the largest closely held companies headquartered ... ranked from 2008-2016. In addition, Standard Process was awarded the Talent Award for ...
(Date:11/30/2016)... ... 2016 , ... The Cronovo Smartwatch, the first on the ... at an affordable price, is now available on the crowdfunding website Kickstarter ... changer” when it comes to the smartwatch. , "With Cronovo, we’ve combined the ...
Breaking Medicine News(10 mins):